A new oral treatment for advanced pancreatic cancer has shown unprecedented results in a major clinical trial, nearly doubling how long patients live compared to standard chemotherapy. The drug, called daraxonrasib, achieved a median overall survival of 13.2 months for patients, a dramatic improvement over the 6.7 months typically seen with chemotherapy alone, according to its developer, the clinical oncology company Revolution Medicines.
Unprecedented Survival Benefit
The data comes from the ongoing Phase 3 RASolute 302 trial involving 500 patients. The company reported that the trial met all its primary and key secondary endpoints, showing that daraxonrasib reduced the risk of death by 60% compared to chemotherapy, a result described as statistically significant with a hazard ratio of 0.40. Dr. Brian Wolpin, a professor of medicine at Harvard Medical School and the trial’s principal investigator, stated he believes the new approach will be “practice-changing” for treating metastatic pancreatic cancer that has progressed after prior treatment.
This advance addresses a critical need. Pancreatic cancer is the deadliest major cancer, with an overall five-year survival rate of just over 5% in the UK. For those diagnosed at a late stage, the prognosis is particularly dire; in England, only around 8% survive one year. In the US, it is the third-leading cause of cancer deaths. “Treatments that can help extend survival are so crucial,” Dr. Wolpin said.
Targeting the ‘Undruggable’ RAS Gene
The revolutionary potential of daraxonrasib lies in its precise biological mechanism. It is designed to block a mutated gene called RAS, a key driver in many cancers, including the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). For decades, RAS mutations have been considered “undruggable” by conventional medicines.
Daraxonrasib, also known as RMC-6236, is what scientists call an oral, RAS(ON) multi-selective, non-covalent inhibitor. Revolution Medicines developed it using a proprietary “Tri-Complex Inhibitor Platform.” Unlike earlier attempts, this technology allows the drug to target the active, GTP-bound form of multiple common RAS mutations. By effectively switching off this fundamental cancer-causing signal, the pill represents a more personalised, targeted approach than broadly toxic chemotherapy.
The company’s focus extends beyond pancreatic cancer; it is also evaluating daraxonrasib in Phase 3 trials for non-small cell lung cancer and believes it has potential for a broad range of “RAS-addicted” cancers. Revolution Medicines has secured significant resources to pursue this goal, including a $2 billion flexible funding agreement with Royalty Pharma to support global development and commercialisation while retaining control of its portfolio.
Regulatory Pathway and Side Effects
Revolution Medicines has stated it plans to submit the Phase 3 data to the U.S. Food and Drug Administration as part of a future New Drug Application. The FDA has already granted daraxonrasib Breakthrough Therapy and Orphan Drug designations for pancreatic cancer, and the drug was selected for a Commissioner’s National Priority Voucher Program, all aimed at expediting its development.
However, the treatment carries a significant burden of side effects. According to the UK’s clinical trial registry, common issues include rash, vomiting, fatigue, nausea, diarrhea, constipation, inflammation, mouth sores, liver inflammation, decreased red blood cells, scaly skin, and kidney effects. These are broadly similar to chemotherapy side effects, which can also include hair loss, nerve problems, and mood changes, as noted by the American Cancer Society.
The potency and physical toll were underscored by former US Senator Ben Sasse, who revealed he is taking daraxonrasib for stage four pancreatic cancer. He called it a “nasty drug” that caused severe skin issues and bleeding, though he also reported his tumours had shrunk by 76%. Oncologists caution that while early data is compelling, long-term outcomes in larger patient populations are still being established.
The search for better treatments is paralleled by efforts to improve late diagnosis, a major factor in pancreatic cancer’s high mortality. In the UK, where around 11,100 new cases are diagnosed annually, initiatives are underway, including a national early detection study (UK-EDI) for high-risk individuals and trials for a pioneering breath test that could detect the disease in its earliest stages.
